Epidiolex (cannabidiol) is used to treat seizures due to Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. It's available as an oral solution (liquid) that can be taken by people aged 1 year and older. The dosage is based on body weight and is taken by mouth twice a day. Potential side effects include drowsiness, diarrhea, and poor appetite. Epidiolex (cannabidiol) currently doesn't have a generic version available.
Seizures due to Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex
Epidiolex (cannabidiol) is a cannabinoid (CBD). It's made from the Cannabis sativa plant (marijuana). The way it works to treat seizures isn't known, but it's thought to work on receptors in the brain to help calm brain cells down.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Treats seizures linked to rare conditions (LGS, DS, and TSC)
Available as a liquid, which is helpful for people who have trouble swallowing pills
Can be given to children as young as 1 year of age
Not a controlled substance
Can make you very sleepy
Can cause serious changes in mood and behavior
Stopping it suddenly can result in more frequent or longer seizures
Might not be safe if you have liver problems
Take Epidiolex (cannabidiol) with or without food, but be sure to take it the same way each time. Food can affect how much medication your body absorbs, so consistency is key to keeping steady levels of this medication in your body every day.
Be sure to use the bottle adapter and medication dose syringe that Epidiolex (cannabidiol) comes with to measure out your dose. Don't use household teaspoons because they aren't accurate and might cause you to take the wrong amount of medication.
Place the tip of the oral syringe against the inside of the cheek and gently push the plunger until all of Epidiolex (cannabidiol) is given. Don't forcefully push the plunger or aim the syringe to the back of the mouth because this can cause choking.
When you're done using Epidiolex (cannabidiol), leave the adapter in place and screw the cap back on top. Clean the reusable syringe with warm, soapy water and allow it to air dry.
Store Epidiolex (cannabidiol) at room temperature and throw away any unused medication after 12 weeks of opening it, even if there is leftover medication in the bottle.
Epidiolex (cannabidiol) can cause sleepiness. Don't drive or do anything that requires you to be alert until you know how this medication affects you.
Drinking alcohol or taking medications that make you sleepy while taking Epidiolex (cannabidiol) can make you more drowsy and less alert. It's best to speak with your prescriber before mixing these with Epidiolex (cannabidiol).
Contact your care team right away if you notice any mood changes, trouble sleeping, or thoughts about suicide while taking Epidiolex (cannabidiol).
Epidiolex (cannabidiol) can cause liver problems. It's important to follow up with your prescriber about regular blood tests while taking this medication to check your liver health. If you notice yellowing of the skin or eyes (jaundice), nausea, feeling tired, itching, diarrhea, tenderness on the right side of your stomach, call your prescriber right away.
Epidiolex (cannabidiol) might affect the results of drug screenings. If you have a drug test planned, let your lab know that you're taking Epidiolex (cannabidiol).
Stopping Epidiolex (cannabidiol) too quickly can cause withdrawal symptoms such as more frequent or longer seizures (status epilepticus). Instead, with your neurologist on a plan to stop taking Epidiolex (cannabidiol) in a safe way, by slowly lowering your dose.
Epidiolex (cannabidiol) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Taking valproate or clobazam (Onfi) | High dose of Epidiolex (cannabidiol) | History of liver problems
Epidiolex (cannabidiol) can cause liver damage. Your risk is higher if you're taking valproate (e.g., valproic acid (Depakene), divalproex (Depakote)) or clobazam (Onfi) at the same time, taking a high dose of Epidiolex (cannabidiol), or if you have liver problems. Signs of liver problems can include dark urine, feeling tired, upset stomach or stomach pain, nausea, vomiting, or yellowing of skin or eyes. If you notice any of these symptoms, call your prescriber right away. Make sure you go to all of your lab appointments while taking Epidiolex (cannabidiol) so that your liver health can be checked regularly.
Risk factors: Taking with alcohol | Taking other medications that make you less alert
Epidiolex (cannabidiol) can lower your ability to focus, think, and react. Your risk is higher when drinking alcohol or taking other medications that make you drowsy or less alert (e.g., benzodiazepines, opioids). Be careful and avoid activities that require you to be alert, such as driving a car, until you know how this medication affects you. Generally, drowsiness is more common when first starting Epidiolex (cannabidiol) and can get better with continued treatment.
Antiepileptic (antiseizure) medications like Epidiolex (cannabidiol) can raise your risk of suicide or thoughts of suicide. Watch for any new or worsening depression and any unusual changes in mood. Report anything concerning to your prescriber. If you have thoughts of hurting yourself, call 911 or get medical attention right away.
Although rare, Epidiolex (cannabidiol) can cause allergic reactions. Seek medical help if you experience hives, red skin, swelling in your body, or trouble breathing.
Risk factors: Stopping Epidiolex (cannabidiol) too fast
Epidiolex (cannabidiol) can cause withdrawal symptoms such as more frequent and longer seizures (status epilepticus). To lower this risk, make sure to work with your prescriber to stop Epidiolex (cannabidiol) slowly if you need to stop taking this medication.
Your dose depends on what condition you're taking Epidiolex (cannabidiol) for:
Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS): The typical starting dose is 2.5 mg/kg of body weight by mouth twice daily. After one week, your neurologist might raise your dose to 5 mg/kg twice daily. The maximum dose is typically 10 mg/kg twice daily.
Tuberous sclerosis complex (TSC): The typical starting dose is 2.5 mg/kg by mouth twice daily. Your neurologist will raise your dose slowly until you reach a maintenance dose of 12.5 mg/kg twice daily.
Your dose might differ if you have liver problems.
Seizures due to Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex
Bipolar disorder
Seizures (focal impaired awareness seizure, absence seizure)
Migraine prevention
Treatment of seizures from Lennox-Gastaut syndrome in people ages 2 years and older (as an add-on to other anti-seizure medications)
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
Abu-Sawwa, R., et al. (2020). Epidiolex (cannabidiol) primer: Frequently Asked Questions for patients and caregivers. The Journal of Pediatric Pharmacology and Therapeutics.
Devinsky, O., et al. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. The New England Journal of Medicine.
Gray, R. A., et al. (2020). The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders.
Jazz Pharmaceuticals, Inc. (2024). Epidiolex- cannabidiol solution [package insert]. DailyMed.
National Center for Emerging and Zoonotic Infectious Diseases (U.S.). (2018). Spoons are for soup / Milliliters (mL) are for medicine. Centers for Disease Control and Prevention.
National Institute of Neurological Disorders and Stroke. (2024). Dravet syndrome.
Thiele, E. A., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet.
Thiele, E. A., et al. (2021). Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex. Journal of the American Medical Association Neurology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.